Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05815381
Other study ID # 2019-06161
Secondary ID
Status Completed
Phase
First received
Last updated
Start date November 16, 2020
Est. completion date November 22, 2022

Study information

Verified date April 2023
Source Karolinska Institutet
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

A cohort of fibromyalgia (FM) patients (n =90) and healthy controls (HC) (n= 93) was recruited to investigate the associations between human IgG binding to satellite glia cells (SGC) from dorsal root ganglia (DRG) and pathophysiological mechanisms. The study is based on previously identified mechanisms resulting from injecting human IgG antibodies from FM patients, but not HC, in mice (Goebel et al. J Clin Invest. 2021;131(13):e144201). Subjects have been carefully phenotyped using validated questionnaires and quantitative sensory testing (QST) was applied to determine pain sensitivity. A blood sample was taken to quantify anti-SGC IgG, as well as proteins, lipids and metabolites. Skin biopsies were taken to analyze changes in skin innervation (IENFD) and immune cell activation. Magnetic resonance spectroscopy (MRS) and functional magnetic resonance imaging (fMRI) was performed (n=122) to investigate central nervous system pain related mechanisms. Insular glutamate levels, as well as the levels of other brain metabolites will be determined (MRS) and related to symptom severity and anti-SGC IgG levels. Resting state as well as pain related cerebral activation (BOLD) during standardized evoked pain stimuli will be characterized (fMRI) and related to the MRS findings and to anti-SGC IgG levels.


Description:

Visit 1 (duration approx. 2,5-4 hours) Questionnaires: A check of inclusion and exclusion criteria was made, including the palpation of tender points (ACR 1990 FM criteria). Subjects completed a set of validated questionnaires regarding pain (pain intensity ratings on visual analogue scale (VAS), pain duration, pain drawing, Short form McGill), fibromyalgia severity (fibromyalgia impact questionnaire, (FIQ)), sleep (Pittsburgh Sleep Inventory Questionnaire, (PSQI)), fatigue (Multidimensional Fatigue Inventory (MFI-20)), depression/anxiety (Hospital anxiety depression scale (HADS), Becks depression inventory (BDI), State Trait Anxiety Questionnaire (STAI)), pain coping (Coping Strategy Questionnaire (PCS)), acceptance and flexibility (chronic pain acceptance questionnaire (CPAQ-8), acceptance and action questionnaire (SAAQ)), the Tampa Scale for Kinesiophobia (TSK) and health related quality of life (EQ-5D). Quantitative sensory testing: Perception thresholds for non-painful and painful heat/cold were examined using a Thermotest. A thermode (2x2cm) was placed at the skin and the temperature was modulated by a computer (0-50 degrees C). The subject signaled the respective perception by pressing a button, which terminated the stimulation. Subjects were instructed to press the button at the sensation of the slightest warmth/cold and when the heat/cold become painful. Sensitivity to suprathreshold heat/cold pain stimuli were determined by asking the subject to press the button when they would rate a pain intensity corresponding to 4 and 7/10. Pain sensitivity to pressure was assessed by pressure algometry at 8 different sites in the body. The subjects were instructed to press a signal button when the pressure turned into the slightest sensation of pain (pressure pain threshold) and when the pain corresponded to 4 and 7/10, respectively. Blood test: Venous blood tests were taken (maximal volume 50 ml/individual). The levels of human IgG binding to murine satellite glia cells (SGC) will be determined as % SGC binding human IgG. In addition, we will also assess the amount of IgG binding to human DRG sections and possibly also to human SGC (postmortem donors). The blood samples will also be analysed for algogenic and inflammatory substances, lipids and metabolites and immune cell activation, including fluorescence-activated cell sorting (FACS)(in a subgroup). As an extension of the study, IgG antibodies will be purified to evaluate the effect on cell cultures and in the rodent FM model. Skin biopsies: Two punch skin biopsies (4 mm diameter) were performed at the thigh. The skin was sterilized, and anesthetized using a local anesthetic (10mg/ml Xylocain with adrenalin). If needed the was treated with spongostan/BloodStop and a special plaster (Steri-Strip) was always applied for 7-10 days. The skin will be analyzed regarding morphological changes of intradermal small fibres and IENFD and thick myelinated fibers will be determined. In addition, immune cell activation will be assessed using various methods. Visit 2 (duration approx. 1,5 hours) Imaging: The subjects were asked to make a new pain rating (VAS). They were familiarized with the evoked pain stimulus used in the scanner. Following the safety routines to exclude contraindications for MR scanning the subjects were placed in the scanner. The assessment started with structural scans (T1, T2), followed by resting state and MR spectroscopy (anterior and posterior insula) and finally an evoked pain protocol using a series of painful pressure stimuli generated by an automatic pressure applicator at the leg of the subjects, corresponding to 150 and 300kPa, respectively, (blood oxygenation level dependent, BOLD). Aims not specified elsewhere: 1. To run assays aiming at identifying the antigen/antigens and if successful to quantify the specific antibodies and relate them to FM severity. 2. To assess if IgG antibodies form individuals with severe FM activate satellite cell cultures to release pro-inflammatory and algesic substances more efficiently than IgG antibodies from individuals with less severe FM. 3. To investigate if there are abnormalities in the number, characteristics, or activation of immune cells in the blood or skin of FM patients compared to HC. 4. To assess effects of FM IgG on animal models.


Recruitment information / eligibility

Status Completed
Enrollment 183
Est. completion date November 22, 2022
Est. primary completion date November 22, 2022
Accepts healthy volunteers
Gender Female
Age group 20 Years to 65 Years
Eligibility Inclusion Criteria: - Female sex, - age 20-65 years For the FM arm: - fulfilling the ACR 1990 fibromyalgia diagnostic criteria - fulfilling the ACR 2016 fibromyalgia diagnostic criteria Exclusion Criteria: - autoimmune or inflammatory diseases (other than FM in the FMS cohort) - other somatic diseases that could influence the study outcome (e.g. peripheral neuropathy etc) - pain problems (other than FM in the FMS cohort) - severe depression/anxiety that requires specific treatments - medication with anticonvulsants, antidepressants or corticosteroids - inability to refrain from NSAIDs, analgesics, sedatives or sleep medication 48 hours before examinations - inability to communicate in Swedish or other factors that the investigator judges would interfere with the participation in the study - smoking > 5 cigarettes/day - pregnancy - drug or alcohol abuse - contraindications to skin biopsy (allergy to local anesthetics, hemophilia, medication with anticoagulants) - contraindications to fMRI (metal implants, pacemaker)

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Questionnaires, quantitative sensory testing, blood sampling, skin biopsies, functional magnetic resonance imaging, magnetic resonance spectroscopy
se arm/group descriptions

Locations

Country Name City State
Sweden Karolinska Insitutet Stockholm

Sponsors (4)

Lead Sponsor Collaborator
Karolinska Institutet Region Stockholm, The Swedish Rheumatism Ass, Uppsala University

Country where clinical trial is conducted

Sweden, 

Outcome

Type Measure Description Time frame Safety issue
Other Correlations between % SGC IgG and IENFD Spearman correlations (0-1, 1 best correlation) between percent satellite glia cells bound by IgG (% SGC IgG) and intraepidermal nerve fiber density (IENFD)(subgroup of fibromyalgia patients n= 30 and healthy controls n =30) 2 years
Other Correlations between IENFD and glutamate in anterior insula Spearman correlations (0-1, 1 best correlation) between intraepidermal nerve fiber density (IENFD) and glutamate concentrations in anterior insula (subgroup of fibromyalgia patients n= 30 and healthy controls n = 30) 2 years
Other Correlations between IENFD and glutamate in posterior insula Spearman correlations (0-1, 1 best correlation) between intraepidermal nerve fiber density (IENFD) and glutamate concentrations in posterior insula (subgroup of fibromyalgia patients n= 30 and healthy controls n = 30) 2 years
Other Correlations between % SGC IgG and sensitivity to cold pain in FM Spearman correlations (0-1, 1 best correlation) in fibromyalgia (FM) patients between percent satellite glia cells bound by IgG (% SGC IgG, range 0-100%, 100% worst) and cold pain sensitivity (MSA Thermal Stimulator, 32-0 degrees Celsius, 0 degrees least pain sensitive) 2 years
Other Correlations between % SGC IgG and sensitivity to heat pain in FM Spearman correlations (0-1, 1 best correlation) in fibromyalgia (FM) patients between percent satellite glia cells bound by IgG (% SGC IgG, range 0-100%, 100% worst) and heat pain sensitivity (MSA Thermal Stimulator, 32-50 degrees Celsius, 50 degrees least pain sensitive) 2 years
Other Group differences in pressure pain sensitivity Differences in pressure pain sensitivity (pressure algometry, 0-1500kPa, 1500kPa least pain sensitive) between fibromyalgia patients and healthy controls 2 years
Other Group differences in cold pain sensitivity Differences in cold pain sensitivity (MSA Thermal Stimulator, 32-0 degrees Celsius, 0 degrees least pain sensitive) between fibromyalgia patients and healthy controls 2 years
Other Group differences in heat pain sensitivity Differences in heat pain sensitivity (MSA Thermal Stimulator, 32-50 degrees Celsius, 50 degrees least pain sensitive) between fibromyalgia patients and healthy controls 2 years
Primary Group differences in anti-SGC IgG levels Difference in percent satellite glia cells bound by IgG (anti-SGC IgG levels, 0-100%, 100% worst) between fibromyalgia patients and healthy controls 2 years
Primary Resting state cerebral activity and anti-SGC IgG levels in FM Difference in resting state functional magnetic resonance imaging (exploratory approach) between fibromyalgia (FM) patients with high (50% or more) and low (less than 50%) percent satellite glia cells bound by IgG (anti-SGC IgG levels) 2 years
Primary Cerebral activation during pressure pain (150kPa) and anti-SGC IgG levels in FM Difference in blood oxygenation level dependent functional magnetic resonance imaging during evoked pain (150 kPa) between fibromyalgia (FM) patients with high (50% or more) and low (less than 50%) percent satellite glia cells bound by IgG (anti-SGC IgG levels) 2 years
Primary Cerebral activation during pressure pain (300kPa) and anti-SGC IgG levels in FM Difference in blood oxygenation level dependent functional magnetic resonance imaging during evoked pain (300 kPa) between fibromyalgia (FM) patients with high (50% or more) and low (less than 50%) percent satellite glia cells bound by IgG (anti-SGC IgG levels) 2 years
Primary Glutamate concentrations in anterior insula and anti-SGC IgG levels in FM Difference in glutamate levels, magnetic resonance spectroscopy of anterior insula, between fibromyalgia (FM) patients with high (50% or more) and low (less than 50%) percent satellite glia cells bound by IgG (anti-SGC IgG levels) 2 years
Primary Glutamate concentrations in posterior insula and anti-SGC IgG levels in FM Difference in glutamate levels, magnetic resonance spectroscopy of posterior insula between fibromyalgia (FM) patients with high (50% or more) and low (less than 50%) percent satellite glia cells bound by IgG (anti-SGC IgG levels) 2 years
Primary Cerebral metabolites in anterior insula and anti-SGC IgG levels in FM Differences in magnetic resonance spectroscopy of anterior insula between fibromyalgia (FM) patients with high (50% or more) and low (less than 50%) percent satellite glia cells bound by IgG (anti-SGC IgG levels)(exploratory) 2 years
Primary Cerebral metabolites in posterior insula and anti-SGC IgG levels in FM Differences in magnetic resonance spectroscopy of posterior insula between fibromyalgia (FM) patients with high (50% or more) and low (less than 50%) percent satellite glia cells bound by IgG (anti-SGC IgG levels)(exploratory) 2 years
Secondary Group differences in resting state functional magnetic resonance imaging Difference in resting state functional magnetic resonance imaging (exploratory approach) between fibromyalgia patients and healthy controls 2 years
Secondary Group differences in fMRI BOLD during evoked pressure pain (150 kPa) Difference in blood oxygenation level dependent (BOLD) functional magnetic resonance imaging during evoked pain (150 kPa) between fibromyalgia patients and healthy controls 2 years
Secondary Group differences in fMRI BOLD during evoked pressure pain (300 kPa) Difference in blood oxygenation level dependent functional magnetic resonance imaging during evoked pain (300 kPa) between fibromyalgia patients and healthy controls 2 years
Secondary Group differences in glutamate levels in anterior insula Difference in glutamate levels, magnetic resonance spectroscopy of anterior insula, between fibromyalgia patients and healthy controls 2 years
Secondary Group differences in glutamate levels in posterior insula Difference in glutamate levels, magnetic resonance spectroscopy of posterior insula, between fibromyalgia patients and healthy controls 2 years
Secondary Group differences in cerebral metabolites in anterior insula Differences in magnetic resonance spectroscopy of anterior insula between fibromyalgia patients and healthy controls (exploratory) 2 years
Secondary Group differences in cerebral metabolites in posterior insula Differences in magnetic resonance spectroscopy of posterior insula between fibromyalgia patients and healthy controls (exploratory) 2 years
Secondary Correlations between glutamate in anterior insula and anti-SGC IgG levels in FM Spearman correlations (0-1, 1 best correlation) between glutamate levels in anterior insula, magnetic resonance spectroscopy, and percent satellite glia cells bound by IgG (anti-SGC IgG levels, 0-100%, 100% worst) in fibromyalgia (FM) patients 2 years
Secondary Correlations between glutamate in posterior insula and and anti-SGC IgG levels in FM Spearman correlations (0-1, 1 best correlation) between glutamate levels in posterior insula, magnetic resonance spectroscopy, and percent satellite glia cells bound by IgG (anti-SGC IgG levels, 0-100%, 100% worst) in fibromyalgia (FM) patients 2 years
Secondary Correlations between % SGC IgG and pain intensity in FM Spearman correlations (0-1, 1 best correlation) in fibromyalgia (FM) patients between percent satellite glia cells bound by IgG (% SGC IgG, range 0-100%, 100% worst) and pain intensity assessed by visual analogue scale (VAS, range 0-100, 100 worst) 2 years
Secondary Correlations between % SGC IgG and fibromyalgia severity Spearman correlations (0-1, 1 best correlation) in fibromyalgia (FM) patients between percent satellite glia cells bound by IgG (% SGC IgG, range 0-100%, 100% worst) and fibromyalgia impact questionnaire (FIQ, range 0-100%, 100% most severe fibromyalgia) 2 years
Secondary Correlations between % SGC IgG and sensitivity to pressure pain in FM Spearman correlations (0-1, 1 best correlation) in fibromyalgia (FM) patients between percent satellite glia cells bound by IgG (% SGC IgG, range 0-100%, 100% worst) and pressure pain sensitivity (pressure algometry, 0-1500kPa, 1500 kPa least pain sensitive) 2 years
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05659862 - Digitally Assisted Behavioral Physical Activity Intervention in Fibromyalgia N/A
Recruiting NCT03207828 - Testing Interventions for Patients With Fibromyalgia and Depression N/A
Completed NCT03042728 - Impact of Inclusion of a Therapy Dog Visit as Part of the Fibromyalgia Treatment Program N/A
Recruiting NCT06097091 - Effects and Mechanisms of Pain Neuroscience Education in Patients With Fibromyalgia N/A
Recruiting NCT04554784 - Effectiveness of Bowen Therapy for Pain Management in Patients With Fibromyalgia N/A
Completed NCT03300635 - Metabolism, Muscle Function and Psychological Factors in Fibromyalgia N/A
Recruiting NCT06166563 - Exercise, Irritable Bowel Syndrome and Fibromyalgia N/A
Completed NCT03227952 - Sensory Stimulation in Fibromyalgia N/A
Completed NCT03166995 - Postural Exercises in Women With Fibromyalgia N/A
Recruiting NCT06237595 - Vagus Nerve Stimulation in Fibromyalgia N/A
Completed NCT01888640 - Fibromyalgia Activity Study With Transcutaneous Electrical Nerve Stimulation (FAST) N/A
Completed NCT03641495 - Pain Education and Therapeutic Exercise for Fibromyalgia N/A
Recruiting NCT05581628 - FREQUENCY OF FIBROMYALGIA IN PATIENTS WITH CELIAC DISEASE
Active, not recruiting NCT05128162 - Open-label Study to Assess the Safety and Efficacy of Psilocybin With Psychotherapy in Adult Participants With Fibromyalgia Phase 2
Completed NCT04674878 - Comparison of Muscle Energy Techniques and Breathing Exercises for Functional Improvement in Fibromyalgia N/A
Active, not recruiting NCT04084795 - Augmentation of EMDR With tDCS in the Treatment of Fibromyalgia N/A
Completed NCT03129906 - Impact of the Restriction of Sources of Gluten in Fibromyalgia Patients N/A
Completed NCT05058911 - Exposure-based Cognitive Behavior Therapy vs Traditional Cognitive Behavior Therapy for Fibromyalgia N/A
Recruiting NCT04571528 - Effectiveness of VIRTUAL FIBROWALK STUDY N/A
Recruiting NCT04571853 - New Educational Tool for FM N/A